We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.026 | -1.79% | 1.425 | 1.402 | 1.448 | 1.42 | 1.41 | 1.42 | 3,614,132 | 16:35:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -6.69M | -0.0059 | -2.39 | 16.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/4/2020 11:48 | 250k at 1.79 news due? | purple11 | |
16/4/2020 11:47 | 200kbuy at 1.75 full ask.... | purple11 | |
16/4/2020 11:44 | lets hope it can sustain some decent rises now.looking strong atm gl | purple11 | |
16/4/2020 10:38 | Re Post 1489 Astra Zeneca are mentioned in The Pharma Letter dated yesterday (April 15, 2020). I do not subscribe so cannot confirm for sure, if the entry below refers to the same story. The Pharma Letter Another blood cancer drug shows promise for COVID-19 15-04-2020 As global COVID-19 research continues apace, British drugmaker AstraZeneca has entered the fray with….. | tullynessle | |
16/4/2020 10:31 | Well worth reading - the reference to "immunised humanised mice" at the Extract below, may be of interest; especially if a "need" for such an asset is emanating from similar research currently being undertaken throughout the global pharmaceutical industry. Extract: "Its scientists are exploring three potential sources for antibodies against the virus that causes Covid-19, known as SARS CoV-2 – patients who have recovered from the disease, immunised humanised mice and laboratory techniques such as phage display." Cambridge Independent AstraZeneca targets clinical tests of new Covid-19 antibody treatments in ‘three to five months’ Published: 00:01, 11 April 2020 AstraZeneca is aiming to carry out clinical evaluation of new Covid-19 treatments in three to five months. The biopharmaceutical company, headquartered in Cambridge, has confirmed it is using a variety of techniques to develop monoclonal antibodies and is teaming up with government agencies and academia to accelerate the work. Its scientists are exploring three potential sources for antibodies against the virus that causes Covid-19, known as SARS CoV-2 – patients who have recovered from the disease, immunised humanised mice and laboratory techniques such as phage display. AstraZeneca said it has more than 50 virology, protein engineering, clinical and bioprocess experts across biopharmaceuticals R&D and operations working on the drive to find novel antibodies that can bind to the virus and neutralise it. Article continues....... | tullynessle | |
16/4/2020 09:35 | same old problem. daytraders | purple11 | |
16/4/2020 09:04 | Hello hello | orchestralis | |
16/4/2020 08:40 | full ask beingpaid.v cheap down here | purple11 | |
16/4/2020 08:25 | they are working on a "key"for their car t.we may hear something on that. | purple11 | |
15/4/2020 15:58 | What are we waiting for? | scaramouche1941 | |
15/4/2020 15:28 | What makes you say that? | on target | |
15/4/2020 14:58 | Hold on tight lads and lasses Not much longer to wait... | clever_trevor6 | |
14/4/2020 09:10 | hopefully recover to the 1.80 placing price.dont see why not.gl | purple11 | |
13/4/2020 20:48 | im doing the best I can. | purple11 | |
13/4/2020 10:27 | Your so funny hatey | onceatrader |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions